PMID- 3486904
OWN - NLM
STAT- MEDLINE
DCOM- 19860707
LR  - 20111117
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 136
IP  - 12
DP  - 1986 Jun 15
TI  - Quantitative aspects of lupus anti-DNA autoantibody specificity.
PG  - 4581-7
AB  - In this study we have attempted to define the cross-reactive potential of SLE 
      anti-DNA antibodies (in 19 representative sera and plasmas) in both the solution 
      phase and the solid phase. We used the Farr and RBC-CF solution phase assays to 
      measure quantitatively the ability of a variety of negatively charged 
      structurally unrelated molecules to inhibit antibody binding to both native DNA 
      (nDNA) and denatured DNA (dDNA). The inhibitors used were of two types: 1) 
      phospholipids (cardiolipin, phosphatidyl glycerol, and phosphatidic acid) and 2) 
      repeating negatively charged molecules (poly-glutamic acid, heparin sulfate, and 
      chondroitin sulfate). We found in both assays that the phospholipids could 
      inhibit antibody binding to nDNA and dDNA, but a large excess (about 1500-fold) 
      of these molecules was needed relative to DNA to achieve equivalent levels of 
      inhibition. The repeating negatively charged molecules did not inhibit DNA 
      binding at equivalent molar levels as the phospholipids; generally, at least a 
      10,000-fold excess was needed relative to the nucleic acids to achieve any 
      appreciable inhibition. Results of a dDNA binding-inhibition solid-phase ELISA 
      for cross-reactivity of the anti-DNA antibodies gave quite similar results. 
      Finally, we found that eight of the SLE samples did have anti-cardiolipin 
      antibodies, as demonstrated in a cardiolipin-based ELISA. These results suggest 
      that previous reports describing an apparent cross-reactivity of anti-DNA 
      antibodies may not represent physiologically relevant interactions between 
      anti-DNA antibodies and non-nucleic acid antigens.
FAU - Edberg, J C
AU  - Edberg JC
FAU - Taylor, R P
AU  - Taylor RP
LA  - eng
GR  - AM 24083/AM/NIADDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Phospholipids)
RN  - 0 (Polymers)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Antibodies, Antinuclear/*analysis
MH  - *Antibody Specificity/drug effects
MH  - Binding Sites, Antibody/drug effects
MH  - Binding, Competitive
MH  - Calibration
MH  - Complement Fixation Tests/standards
MH  - DNA/*immunology/metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Lupus Erythematosus, Systemic/*immunology
MH  - Phospholipids/pharmacology
MH  - Polymers/pharmacology
MH  - Radioligand Assay/standards
EDAT- 1986/06/15 00:00
MHDA- 1986/06/15 00:01
CRDT- 1986/06/15 00:00
PHST- 1986/06/15 00:00 [pubmed]
PHST- 1986/06/15 00:01 [medline]
PHST- 1986/06/15 00:00 [entrez]
PST - ppublish
SO  - J Immunol. 1986 Jun 15;136(12):4581-7.